# Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke

> **NCT02101606** · PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 20 (actual)

## Conditions studied

- Cerebral Infarction
- Brain Ischemia
- Stroke

## Interventions

- **DRUG:** Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

## Key facts

- **NCT ID:** NCT02101606
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101606, "Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02101606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*